# Amneal Pharmaceuticals, Inc. (AMRX) FY2026 YTD Q2 P&L / Income Statement

- Company: Amneal Pharmaceuticals, Inc. (AMRX)
- Period: 2026-01-01 to 2026-06-30
- Filing: Q2 FY2026 10-Q, filed 2026-08-06, accession number 0001723128-26-000031
- Page: https://plicit.ai/financials/amrx/fy2026-ytd-q2-income-statement
- Chart image: https://plicit.ai/charts/amrx-fy2026-ytd-q2-income-statement-sankey.png

## Chart details: Revenue by Business Segment by Product and Service

Income statement for 2026-01-01 through 2026-06-30. View: Segments by Product and Service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Net revenue**: 1,518,716,000 US dollars
- **Cost of goods sold**: 864,095,000 US dollars
- **Gross profit**: 654,621,000 US dollars
- **Operating costs, net of other operating items (calculated)**: 383,080,000 US dollars
- **Operating income**: 271,541,000 US dollars
- **Total other expense, net**: negative 120,375,000 US dollars
- **Income before income taxes**: 151,166,000 US dollars
- **Provision for income taxes**: 3,552,000 US dollars
- **Net income**: 147,614,000 US dollars
- **Affordable Medicines - Biosimilar**: 51,429,000 US dollars
- **Affordable Medicines - Auto-Injector**: 104,126,000 US dollars
- **Affordable Medicines - Injectable**: 106,721,000 US dollars
- **Affordable Medicines - International**: 12,932,000 US dollars
- **Affordable Medicines - Oral liquid**: 22,463,000 US dollars
- **Affordable Medicines - Oral solid**: 346,272,000 US dollars
- **Affordable Medicines - Other dosage forms**: 128,206,000 US dollars
- **Affordable Medicines - Transdermal**: 141,001,000 US dollars
- **AvKARE - Government label**: 110,156,000 US dollars
- **AvKARE - Institutional**: 21,931,000 US dollars
- **AvKARE - Distribution**: 176,079,000 US dollars
- **AvKARE - Other**: 14,840,000 US dollars
- **Specialty - Central nervous system**: 178,727,000 US dollars
- **Specialty - Hormonal / allergy**: 78,031,000 US dollars
- **Specialty - License agreement**: 0 US dollars
- **Specialty - Other therapeutic classes**: 25,802,000 US dollars
- **Selling, general and administrative**: 287,582,000 US dollars
- **Research and development**: 77,400,000 US dollars
- **Intellectual property legal development expenses**: 3,629,000 US dollars
- **Restructuring and other charges**: 1,204,000 US dollars
- **Acquisition costs**: 12,753,000 US dollars
- **Other operating income**: negative 8,239,000 US dollars
- **Charges (credit) related to legal matters, net**: 8,751,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
- Of which attributable to Amneal Pharmaceuticals, Inc.: $119.92 M; to noncontrolling interests: $27.70 M.

## Chart details: Revenue by Business Segment

- Page: https://plicit.ai/financials/amrx/fy2026-ytd-q2-income-statement/revenue-by-business-segment
- Chart image: https://plicit.ai/charts/amrx-fy2026-ytd-q2-revenue-by-business-segment-sankey.png

Income statement for 2026-01-01 through 2026-06-30. View: Business segment. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Net revenue**: 1,518,716,000 US dollars
- **Cost of goods sold**: 864,095,000 US dollars
- **Gross profit**: 654,621,000 US dollars
- **Operating costs, net of other operating items (calculated)**: 383,080,000 US dollars
- **Operating income**: 271,541,000 US dollars
- **Total other expense, net**: negative 120,375,000 US dollars
- **Income before income taxes**: 151,166,000 US dollars
- **Provision for income taxes**: 3,552,000 US dollars
- **Net income**: 147,614,000 US dollars
- **Affordable Medicines**: 913,150,000 US dollars
- **Specialty**: 282,560,000 US dollars
- **AvKARE**: 323,006,000 US dollars
- **Selling, general and administrative**: 287,582,000 US dollars
- **Research and development**: 77,400,000 US dollars
- **Intellectual property legal development expenses**: 3,629,000 US dollars
- **Restructuring and other charges**: 1,204,000 US dollars
- **Acquisition costs**: 12,753,000 US dollars
- **Other operating income**: negative 8,239,000 US dollars
- **Charges (credit) related to legal matters, net**: 8,751,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
- Of which attributable to Amneal Pharmaceuticals, Inc.: $119.92 M; to noncontrolling interests: $27.70 M.